Biocon has received a setback in its attempts to gain US approval for human insulin, after the US Food and Drug Administration issued a complete response letter calling for more information on the filing, as well as urging the biosimilars developer to deliver on remediation plans at its Indian manufacturing facilities in Bangalore.
“The US FDA has issued a CRL for the biologics license application for the Insulin-R product filed by Biocon Biologics,”...






